Enjoy complimentary customisation on priority with our Enterprise License!
The global head and neck cancer diagnostics market size is estimated to grow by USD 4,937.16 million at a CAGR of 12.2% between 2022 and 2027.
To control and fight cancer, private and government agencies have several initiatives that help to promote cancer awareness, diagnosis, and treatment. For example, the American Cancer Society, founded in 1913, works to reduce the risk of cancer. Its global health programs include global anti-cancer efforts, focused on preventing cancer, saving lives, and alleviating suffering. Furthermore, the existence of such initiatives that aim to address the global problem of cancer, rather than just covering a specific region, will promote acceptance of cancer diagnoses, including head and neck cancer, and In turn, will drive the growth of the market during the forecast period.
Technavio has segmented the market into Diagnostic Methods, End-user and Geography
It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2017 to 2021, besides analyzing the current market scenario.
To learn more about this report, Request Free Sample
The market share growth by the biopsy and blood tests segment will be significant during the forecast period. A biopsy is a laboratory procedure in which a piece of tissue or cell sample is removed for analysis in a laboratory. A biopsy is done to diagnose cancer. Biopsies to diagnose head and neck cancer include incisional biopsy, fine needle aspiration (FNA) biopsy, and human papillomavirus (HPV) testing.
Get a glance at the market contribution of various segments View a PDF Sample
The biopsy and blood tests segment was valued at USD 1,511.10 million in 2017. Blood tests to detect head and neck cancer include liver function tests (LFTs), cell counts, and measuring antibodies to Epstein-Barr virus (EBV). As biopsies and blood tests can be performed even after performing other diagnostic methods, this segment is expected to contribute the largest revenue share to the global head and neck cancer diagnostics market during the forecast period.
Head and neck cancer diagnostic products offer a variety of benefits to hospitals and clinics at different levels and in different roles, including driving cost savings by improving patient care and satisfaction, improving point-of-care operations, and enhancing sales performance. In addition, healthcare providers are focused on improving technological capabilities and developing head and neck cancer diagnostic methods that are compatible with remote access devices and mobile phone apps to quickly obtain accurate diagnostic results. Therefore, such factors are expected to drive the growth of the hospital segment in the global head and neck cancer diagnostic methods market during the forecast period.
A specialty clinic is a facility where patients are admitted for special research or treatment. Specialty clinics empower and energize the global head and neck cancer diagnostics market by advancing science and medical technology. The availability of advanced professionals such as nurse practitioners, clinical nurse specialists, physician assistants, and clinical pharmacists will increase the demand for specialized clinics in the global head and neck cancer diagnostics market during the forecast period.
For more insights about the market share of various regions View PDF Sample now!
North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The US is the largest contributor to the region. Many of the established market players in the head and neck cancer diagnostics market are headquartered in the US. This will make cancer diagnostic equipment widely available to address the increasing incidence of head and neck cancer in the US. Furthermore, the presence of established market players, increasing awareness about HPV-related diseases, and the presence of dedicated head and neck cancer treatment programs are expected to drive the growth of the regional head and neck cancer diagnostics market during the forecast period.
The outbreak of COVID-19 negatively affected the healthcare systems regionally and also had a noteworthy impact on the head and neck cancer diagnostics market in 2020. However, in 2021, the initiation of large-scale vaccination drives?lifted the lockdown and travel restrictions, which led to the resumption of supply chain activities. Thus, such factors will increase the demand for head and neck cancer diagnostics in the region during the forecast period.
Buy Now Full Report and Discover More
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
AbbVie Inc: The company offers head and neck cancer diagnostics such as ABBV 368 for the treatment of solid tumors such as triple negative breast cancer, non small cell lung cancer, ecurrent and metastatic, head and neck squamous cell carcinoma and many more.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.
Increasing incidences of head and neck cancers is the key factor driving the growth of the market. Head and neck cancers include cancers of the oral cavity, throat (nasopharynx, oropharynx, and hypopharynx), larynx, sinuses, nasal cavities, and salivary glands. As of January 2020, head and neck cancer accounts for approximately 4% of all cancers in the US. In 2020, an estimated 562,328 people were diagnosed with head and neck cancer worldwide.
Furthermore, according to the NHS, around 12,000 people are newly diagnosed with head and neck cancer each year in the UK. Moreover, around 8,300 people are diagnosed with oral cancer each year in the UK, which equates to one in every 50 cancers diagnosed. Due to this high incidence of head and neck cancer, the demand for head and neck cancer diagnosis is expected to increase during the forecast period.
The growing trend of oncology tourism is the primary trend shaping the market growth. Oncology treatment can be very costly. In the US, some diagnostic procedures and treatment courses can be very expensive. When people in the US travel to other countries for medical procedures, they save approximately 70 to 80 percent of the total costs incurred domestically, without compromising the quality of treatment or care. Another factor driving medical tourism is the fact that people diagnosed with or suspected of having cancer do not want to wait long for treatment.
Moreover, the most popular destinations for cancer treatment are Germany, Spain, France, India, and Israel. Germany offers superior technology-based treatments, France has the highest success rate in Europe, and Spain focuses on alternative oncology treatment options. Therefore, the growth trend in oncology tourism is expected to have a positive impact on the demand for cancer diagnostics, including the global head and neck cancer diagnostics market during the forecast period.
The potential disadvantages of excise duty on the sale of medical devices is a challenge that affects the growth of the market. Excise taxes raise the price of a product below the full tax amount, and the price burden is shared by producers and consumers. This in turn will limit innovation. According to the Tax Foundation's general equilibrium model, the reinstatement of excise taxes could also cause significant job losses in the medical device industry.
Additionally, most hospitals in the US procure products from manufacturers through GPO at low prices. Therefore, hospitals' bargaining power may make it difficult for manufacturers to pass on the cost burden of this tax. If such tax policies are not abolished, they may pose major challenges to the growth of medical devices and impede the growth of the global head and neck cancer diagnostics market during the forecast period.
Buy Now Full Report and Discover More
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Head and Neck Cancer Diagnostics Market Customer Landscape
The head and neck cancer diagnostics market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Head and Neck Cancer Diagnostics Market Scope |
|
Report Coverage |
Details |
Page number |
183 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 12.2% |
Market growth 2023-2027 |
USD 4,937.16 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
11.02 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 41% |
Key countries |
US, Germany, France, China, and Japan |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Accuray Inc., AdDent Inc., Bristol Myers Squibb Co., Canon Inc., Carestream Health Inc., Eli Lilly and Co., Esaote Spa, Flexicare Group Ltd., General Electric Co., Hitachi Ltd., KARL STORZ SE and Co. KG, Koninklijke Philips N.V., Olympus Corp., Optim LLC, Shimadzu Corp., Siemens AG, Sumitomo Mitsui Financial Group, Xoran Technologies LLC, and Merck KGaA |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Diagnostic Methods
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.